alendronate has been researched along with Asthma in 9 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
Excerpt | Relevance | Reference |
---|---|---|
"We have recently shown that long-term use of inhaled corticosteroids decreases bone mineral density (BMD) of the lumbar spine in postmenopausal asthmatic women." | 6.71 | Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. ( Fujita, K; Fujita, M; Goya, K; Kasayama, S; Kawase, I; Miyatake, A; Morimoto, Y; Yamamoto, H, 2005) |
" Seventy-eight participants with persistent asthma receiving 250 μg of fluticasone twice daily for 2 weeks were randomized to receive alendronate or placebo while initiating salmeterol for 8 weeks." | 5.30 | Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate. ( Boushey, HA; Cardet, JC; Castro, M; Chinchilli, VM; Codispoti, CD; Dyer, AM; Gerard, N; Holguin, F; Israel, E; Jiang, X; Kraft, M; Lazarus, S; Lemanske, RF; Lu, Q; Lugogo, N; Mauger, D; McIntire, K; Moore, WC; Moy, J; Ortega, VE; Peters, SP; Smith, LJ; Solway, J; Sorkness, CA; Sumino, K; Wechsler, ME; Wenzel, S, 2019) |
"A 6-year-old East Indian boy with asthma was mistakenly given alendronate, a bisphosphonate, for 3 months instead of montelukast, a leukotriene-receptor antagonist." | 3.72 | Dispensing error leading to alendronate ingestion. ( Bailey, B; Carrière, B; Chabot, G; Lebel, D, 2003) |
"We have recently shown that long-term use of inhaled corticosteroids decreases bone mineral density (BMD) of the lumbar spine in postmenopausal asthmatic women." | 2.71 | Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. ( Fujita, K; Fujita, M; Goya, K; Kasayama, S; Kawase, I; Miyatake, A; Morimoto, Y; Yamamoto, H, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 7 (77.78) | 29.6817 |
2010's | 1 (11.11) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cardet, JC | 1 |
Jiang, X | 1 |
Lu, Q | 1 |
Gerard, N | 1 |
McIntire, K | 1 |
Boushey, HA | 1 |
Castro, M | 1 |
Chinchilli, VM | 1 |
Codispoti, CD | 1 |
Dyer, AM | 1 |
Holguin, F | 1 |
Kraft, M | 1 |
Lazarus, S | 1 |
Lemanske, RF | 1 |
Lugogo, N | 1 |
Mauger, D | 1 |
Moore, WC | 1 |
Moy, J | 1 |
Ortega, VE | 1 |
Peters, SP | 1 |
Smith, LJ | 1 |
Solway, J | 1 |
Sorkness, CA | 1 |
Sumino, K | 1 |
Wechsler, ME | 1 |
Wenzel, S | 1 |
Israel, E | 1 |
Pala, G | 1 |
Perfetti, L | 1 |
Cappelli, I | 1 |
Caminati, M | 1 |
Moscato, G | 1 |
Isik, A | 1 |
Uras, I | 1 |
Uyar, ME | 1 |
Karakurt, F | 1 |
Kaftan, O | 1 |
Carrière, B | 1 |
Bailey, B | 1 |
Chabot, G | 1 |
Lebel, D | 1 |
Kasayama, S | 1 |
Fujita, M | 1 |
Goya, K | 1 |
Yamamoto, H | 1 |
Fujita, K | 1 |
Morimoto, Y | 1 |
Kawase, I | 1 |
Miyatake, A | 1 |
Smith, BJ | 1 |
Laslett, LL | 1 |
Pile, KD | 1 |
Phillips, PJ | 1 |
Phillipov, G | 1 |
Evans, SM | 1 |
Esterman, AJ | 1 |
Berry, JG | 1 |
Ornoy, A | 1 |
Wajnberg, R | 1 |
Diav-Citrin, O | 1 |
Goldstein, MF | 1 |
Fallon, JJ | 1 |
Harning, R | 1 |
Lau, EM | 1 |
Woo, J | 1 |
Chan, YH | 1 |
Li, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Proof of Concept Study of Alendronate for Asthma[NCT02230332] | Phase 2/Phase 3 | 78 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Asthma Control Test : Score calculated as the sum total of a 5-item questionnaire. Each item ranges from 1 (poor control) to 5 (good control) so that the range of the total score is 5 to 25. Scores below 20 indicate that asthma is not well controlled. (NCT02230332)
Timeframe: 8 weeks after randomization
Intervention | units on a scale (Mean) |
---|---|
Alendronate | 22.2 |
Placebo | 22.2 |
Peripheral blood mononuclear cells cAMP concentrations measured using isoproterenol (ISO) as a beta-2 adrenergic receptor agonist, and using phosphate buffered saline (PBS) as a positive control. The outcome is expressed as the ratio of cAMP concentration using ISO relative to cAMP concentration using PBS. (NCT02230332)
Timeframe: 8 weeks after randomization
Intervention | ratio (Geometric Mean) |
---|---|
Alendronate | 5.9 |
Placebo | 5.9 |
(NCT02230332)
Timeframe: 8 weeks after randomization
Intervention | parts per billion (Geometric Mean) |
---|---|
Alendronate | 16.8 |
Placebo | 15.4 |
(NCT02230332)
Timeframe: 8 weeks after randomization
Intervention | number of receptors per cell (Geometric Mean) |
---|---|
Alendronate | 1680 |
Placebo | 1863 |
Salivary Alpha Amylase (sAA) levels from saliva samples obtained through passive drooling, before and 1 hour after Salmeterol administration. The outcome is expressed as the ratio of the Post-Salmeterol to the Pre-Salmeterol sAA levels. (NCT02230332)
Timeframe: 8 weeks after randomization
Intervention | ratio (Mean) |
---|---|
Alendronate | 1.6 |
Placebo | 1.6 |
Following administration of Salmeterol, the concentration of Methacholine required to produce a 20% drop in FEV1 - measured in mg/ml and reported on log base 2 scale. (NCT02230332)
Timeframe: 8 weeks after randomization
Intervention | mg/ml on log base 2 scale (Mean) |
---|---|
Alendronate | 1.8 |
Placebo | 1.7 |
1 review available for alendronate and Asthma
Article | Year |
---|---|
Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease.
Topics: Administration, Inhalation; Administration, Oral; Adult; Alendronate; Asthma; Bone Density; Bone Rem | 1999 |
4 trials available for alendronate and Asthma
Article | Year |
---|---|
Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Alendronate; Asthma; Double-Blind Method | 2019 |
Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Alendronate; Asthma; Bone and Bones; Bone | 2005 |
Randomized controlled trial of alendronate in airways disease and low bone mineral density.
Topics: Absorptiometry, Photon; Aged; Alendronate; Asthma; Bone Density; Bone Density Conservation Agents; F | 2004 |
Alendronate for the prevention of bone loss in patients on inhaled steroid therapy.
Topics: Administration, Inhalation; Alendronate; Asthma; Bone Density; Double-Blind Method; Female; Glucocor | 2001 |
4 other studies available for alendronate and Asthma
Article | Year |
---|---|
Occupational rhinitis to sodium alendronate.
Topics: Adult; Alendronate; Asthma; Female; Humans; Occupational Diseases; Occupational Exposure; Rhinitis | 2008 |
Alendronate-induced asthma.
Topics: Alendronate; Asthma; Bone Density Conservation Agents; Drug Hypersensitivity; Female; Humans; Middle | 2009 |
Dispensing error leading to alendronate ingestion.
Topics: Acetates; Alendronate; Asthma; Calcium Channel Blockers; Child; Cyclopropanes; Drug Packaging; Esoph | 2003 |
The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment.
Topics: Adult; Alendronate; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Berylliosi | 2006 |